Introduction {#Sec1}
============

Beckwith-Wiedemann syndrome (BWS) (OMIM 130650) is an overgrowth disorder with predisposition to embryonal tumor development. Its clinical symptoms include macrosomia, macroglossia, and abdominal wall defects, whereas minor features include ear pits, hypoglycemia, nephromegaly, and hemihypertrophy. BWS is clinically heterogeneous, and the major features may not manifest immediately after birth but appear in the first month of life \[[@CR1]\].

Most cases (about 85%) of BWS result from various genetic and epigenetic aberrations in the imprinted region on chromosome 11p15.5. This region contains two imprinting centers: *H19* TSS DMR (transcription start site differentially methylated region) and *KCNQ1OT1* TSS DMR. The former regulates the transcription of genes *IGF2* and *H19*, whereas the latter regulates, among others, *KCNQ10T1* and *KCNQ1* \[[@CR2]\] in a tissue-dependent manner. About 50% of these cases are caused by a loss of methylation at *KCNQ1OT1* TSS DMR on the maternal chromosome and 20% by paternal uniparental disomy (UPD) of 11p15.5. Up to 5% have a gain of methylation on the maternal chromosome at *H19* TSS DMR. Between 5% and 10% of the cases are caused by a mutation in the maternal copy of *CDKN1C*. Finally, some cases are caused by chromosomal aberrations on chromosome 11, for example, microdeletions (\< 1%), translocations (\< 1%), inversions (\< 1%), or duplications (\< 1%) within the imprinted region of 11p15 (2). Furthermore, hypomethylation in a large number of imprinting disorders (IDs) occurs not only at a single locus but also at other imprinted loci. This phenomenon is known as multi-locus imprinting disturbance (MLID) and can be seen in about 30% of BWS with hypomethylation at *KCNQ1OT1* \[[@CR3]\]. In about 15% of BWS, no (epi)genetic cause can be found (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR4]\].Fig. 1(Epi)genetic aberrations in BWS

The aim of this study was to identify new BWS-related epigenetic loci in a group of patients with unknown (epi)genetic cause. We searched for regions with altered methylation in known imprinted genes in each patient and regions with altered methylation shared between patients in the whole methylome.

Methods {#Sec2}
=======

DNA was isolated from whole blood samples using Gentra Chemicals (Qiagen).

Patient population {#Sec3}
------------------

### BWS patients {#Sec4}

Twenty-five BWS patients (BWS1--BWS25) were devoid of any methylation defect in the imprinted region on chromosome 11p15.5 and a mutation in *CDKN1C*, as determined in the genome diagnostics department of the Academic Medical Center (the Netherlands). The imprinting defect at 11p15.5 was excluded using high resolution melting analysis (HRMA) \[[@CR5]\] and/or methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA). For both the methods, the limit of detection was 10% of alteration of methylation in comparison to negative controls. Maternally inherited mutations in *CDKN1C* were excluded using Sanger sequencing (see Additional file [1](#MOESM1){ref-type="media"}).

All the patients fulfilled the BWS criteria of DeBaun, displaying at least two of the five most common BWS features, including macrosomia, macroglossia, abdominal wall defects, ear creases/pits, and hypoglycemia \[[@CR6], [@CR7]\].

### Positive controls (MLID-BWS) {#Sec5}

We used five DNA samples from MLID-BWS patients with known hypomethylation at *KCNQ1OT1* TSS DMR and other imprinted loci as a positive control group to determine the robustness of this test. Hypomethylation in these patients was previously determined and described by Bliek et al. in 2008 \[[@CR8]\]. The additional hypomethylated loci in these patients were as follows:MLID-BWS1: *MEST*, *GNAS_AS1*;MLID-BWS2: *GNAS_AS1*;MLID-BWS3: *GNAS_AS1*, *DIRAS3*;MLID-BWS4: *MEST*; andMLID-BWS5: *GBR10A*, *GNAS_AS1*, *SNRPN*.

### Control group {#Sec6}

Twenty-six DNA samples from healthy anonymous individuals were used as a normal control group.

HumanMethylation450 array {#Sec7}
-------------------------

The HumanMethylation450 array (Illumina, San Diego, USA) was used to obtain genome-wide methylation levels. This array comprises 485,000 CpG sites throughout the genome and covers 99% of RefSeq genes and 96% of CpG islands. In order to reduce technical bias, patients and controls were randomly divided over the analysis. DNA was bisulfite converted using the EZ DNA methylation kit of ZYMO® and subsequently submitted for analysis on the HumanMethylation450 array, outsourced to GenomeScan, Leiden, The Netherlands (ISO/IEC 17025 approved). The quality of raw methylation data was assessed using the MethylAid script in R (*GenomeScan*'*s Guidelines for Successful Methylation Experiments Using the Illumina Infinium*® *HumanMethylation BeadChip*). All the samples met the quality criteria. To analyze our data, we used a statistical method for single-sample analysis described by Rezwan et al. \[[@CR9]\] adapted to a MINFI package in R (based on the Crawford-Howell *t* test). Prior to this analysis, all probes known to involve polymorphic sites (minor allele frequency, MAF \> 0.01), cross-hybridization probes, and probes located on sex chromosomes were removed from the dataset. The workflow and QC details are depicted in the Additional file [1](#MOESM1){ref-type="media"}. The 450 k data was normalized with the function preprocessFunnorm of MINFI \[[@CR10]\].

Differentially methylated positions (DMP) with assigned adjusted *P* value for M-values smaller than 0.05 were considered as significant (adjusted according to the false discovery rate; FDR).

Searching for DMRs at imprinted loci {#Sec8}
------------------------------------

Next, we determined whether significant DMPs were located in the imprinted regions. To correctly identify imprinted regions in our data, we used chromosomal locations for imprinted DMRs published by the European Network for Human Congenital Imprinting Disorder. These regions will be referred to as COST regions. (standardized nomenclature for imprinted loci/DMR; <http://www.imprinting-disorders.eu/?page_id=3154>). Note that COST regions in imprinted loci are differentially methylated alleles. (GenomicRanges version 1.28; R-software).

We calculated the percentage of significant DMPs that were located in COST regions for each patient. Further, to avoid false-positive results, only COST regions with two or more significant DMPs were considered as potential aberrantly methylated regions.

Searching for new DMRs shared between BWS patients {#Sec9}
--------------------------------------------------

To test whether significant DMPs occurred in two or more BWS patients, we carried out a comparative analysis: (1) first, we selected significant DMPs based on the adj.*P*value_M \< 0.05 per patient, taking into account the direction of aberration (hypomethylated; hypermethylated); (2) then, we compared selected DMPs between patients and filtered out DMPs that occurred in more than one BWS patient; (3) the last filter step involved a selection of at least two significant DMPs within the region (based on the gene name and index number of CpG sites). MLID-BWS patients were included in this analysis.

The implementation of these filter steps allowed for the identification of DMPs showing recurrent altered methylation in BWS patients rather than the biggest effect of size and/or the smallest *P* value.

Results {#Sec10}
=======

HumanMethylation450 array {#Sec11}
-------------------------

In order to test the ability of the HumanMehylation450 array to detect alterations of methylation in BWS, we tested five MLID-BWS patients with known epimutations. Significant DMPs were seen in all known aberrantly methylated regions *(KCNQ1OT1*, *DIRAS3*, *GNAS*-*AS1*, *MEST*, *GRB10*, and *SNRPN*), indicating that this platform can detect methylation defects in BWS. Moreover, by using this method, we identified hypomethylation in 18 other imprinted loci *(DIRAS3_Ex2*, *IGF1R*, *GNAS*-*XL*, *WRB*, *FAM50B*, *FANCC*, *GNAS*-*A/B*, *NHP2L1*, *ERLIN2*, *MAGEL2*, *MCTS2P*, *PPIEL*, *PEG10*, *RB1*, *NDN*, *SNRPN_5′DMR4*, *SNRPN_variant4*, and *L3MBTL1*) and hypermethylation in two imprinted loci (*ZDBF2* and *GNAS*-*NESP*), which were not known to be aberrantly methylated in these five MLID-BWS patients (Table [1](#Tab1){ref-type="table"}).Table 1Imprinted loci in MLID BWS patients detected by HumanMethylation450 array (Illumina)MLID BWS1MLID BWS2MLID BWS3MLID BWS4MLID BWS5Number of patientsHypomethylated KCNQ1OT1●●●●●5 DIRAS3○●○--○4 DIRAS3_Ex2○○○--○4 GNAS-AS1●●●--●4 GNAS-XL○○○--○4 WRB--○○○○4 IGF1R----○○○3 FAM50B--○○--○3 FANCC--○○--○3 GNAS-A/B○○○----3 NHP2L1--○○--○3 MEST●----●--2 ERLIN2--○----○2 MAGEL2○------○2 MCTS2P----○--○2 PPIEL--------○1 GRB10--------●1 PEG10------○--1 RB1○--------1 NDN--------○1 SNRPN_5′DMR4--------○1 SNRPN_variant4--------○1 SNRPN/SNURF--------●1 L3MBTL1○--------1Hypermethylated ZDBF2○○○--○4 GNAS-NESP----○----1● and ○ aberrant methylation detected by HumanMethylation array (Illumina)● previously known to be hypomethylated

We performed a single-sample analysis for each patient in our BWS cohort. The number of significantly hypomethylated DMPs per patient ranged from 184 (BWS3) to 967 (BWS24) while that of significantly hypermethylated DMPs ranged from 148 (BWS16) to 12,931 (BWS24) (Table [2](#Tab2){ref-type="table"}).Table 2Number and percentage of significant DMPs per patient in 450 KPatient_IDNumber of hypermethylated DMPs% hypermethylated DMPs in 450 KPatient_IDNumber of hypomethylated DMPs% hypomethylated DMPs in 450 K*BWS2412,9313.02*BWS249670.23*BWS2585041.98*MLID BWS28820.21MLID BWS218970.44MLID BWS38330.19BWS716190.38BWS256420.15MLID BWS412750.30MLID BWS15860.14MLID BWS110820.25MLID BWS55350.12MLID BWS310700.25BWS105220.12BWS510390.24BWS94820.11BWS109950.23MLID BWS44670.11BWS18050.19BWS114330.10BWS227490.17BWS73380.08BWS116690.16BWS183370.08BWS45520.13BWS23320.08BWS84530.11BWS173270.08BWS34310.10BWS63180.07BWS94210.10BWS223060.07BWS24030.09BWS193020.07MLID BWS53220.08BWS52940.07BWS63030.07BWS162930.07BWS152990.07BWS42820.07BWS192360.06BWS12790.07BWS172180.05BWS132650.06BWS212150.05BWS232650.06BWS132140.05BWS122640.06BWS232110.05BWS142580.06BWS122100.05BWS152520.06BWS182010.05BWS212480.06BWS141850.04BWS82480.06BWS201740.04BWS202450.06BWS161480.03BWS31840.04

In two patients, BWS24 and BWS25, we found hypermethylation throughout the methylome. We identified almost 13,000 hypermethylated DMPs in BWS24, which is more than 3% of all the informative probes included in the analysis. In BWS25, hypermethylated DMPs, significantly, accounted almost for 2% of all the informative probes. The percentage of hypermethylated DMPs in other patients did not exceed 0.44%.

BWS24 and BWS25 also exhibited a slightly increased number of hypomethylated DMPs in comparison to other BWS patients but not different from MLID-BWS patients. Significantly, hypomethylated DMPs accounted for 0.23% in BWS24 and 0.15% in BWS25 of all the informative probes included in the analysis. In MLID-BWS patients, this percentage ranged from 0.11% to 0.21%.

The analysis of genomic distributions of significant DMPs of these two patients showed their similarity (Fig. [2](#Fig2){ref-type="fig"}). Hypermethylated significant DMPs were overrepresented in 3′ untranslated region (3′UTR), body, OpenSea, and enhancers while hypomethylated significant DMPs were overrepresented in Islands, DNase I hypersensitivity site (DHS), and Promoter_Associated.Fig. 2Genomic distribution of significant DMPs in patients BWS24 and BWS25. The plots compare the percentage of genomic distribution (genomic annotations of HumanMethylation450k array, Illumina) of all the informative probes included in our data and the percentage of genomic distribution of significant DMPs detected in patients BWS24 and BWS25. We compared the distribution of UCSC_RefGene_Group (1st exon, TSS200, TSS1500, 5′UTR, body, 3′UTR), Relation_to_UCSC_CpG_Island (Shore, Shelf, N, S), differentially methylated regions (DMR; CDMR, cancer-specific differentially methylated region; RDMR, reprogramming-specific differentially methylated region), overlapping enhancers loci, Regulatory_Feature_Group (Gene_Associated, Gene_Associated_Cell_type_specific, Promoter_Associated, Promoter_Associated_Cell_type_specific, Unclassified, Unclassified_Cell_type_specific), and DNase I hypersensitivity site (DHS). The number above each bar represents percentage. **a** The comparison of genomic distribution of hypermethylated DMPS in BWS24. **b** The comparison of genomic distribution of hypomethylated DMPs in BWS24. **c** The comparison of genomic distribution of hypermethylated DMPs in BWS25. **d** The comparison of hypomethylated DMPs in BWS25

To exclude the fact that these methylation patterns in these two patients are caused by cell type skewing, we estimated the distribution of cell types (function: estimateCellCounts, R package: FlowSorted.Blood.450k). Both the patients manifested comparable cell type profiles to the other patients in this group.

All significant DMPs per patient are listed in Additional file [2](#MOESM2){ref-type="media"}: Table S1 and Additional file [3](#MOESM3){ref-type="media"}: Table S2.

The estimation of the distribution of cell types and calculated *P* values are listed in Additional file [4](#MOESM4){ref-type="media"}: Table S3 and Additional file [5](#MOESM5){ref-type="media"}: Table S4.

Searching for DMRs at imprinted loci {#Sec12}
------------------------------------

We calculated the percentage of total significant DMPs located in COST regions for each patient and for further analysis considered only COST regions with two or more significant DMPs as significantly aberrant (to avoid false-positive results).

MLID-BWS patients showed the highest percentage of significant DMPs assigned to COST regions, ranging from 3.73% to 17.97%, as expected (Table [3](#Tab3){ref-type="table"}). In BWS24 and BWS25, the percentage of total significant DMPs located in COST regions was slightly high but lower than that in MLID-BWS patients. This percentage was 0.55% in BWS24 and 1.19% in BWS25. In contrast to MLID-BWS, BWS24 and BWS25 displayed hypermethylation in COST regions. However, the number of significant DMPs in these regions was relatively small, and the DMPs were non-consecutive. Both the patients displayed hypermethylation in *H19* TSS DMR (BWS24---8 DMPs, BWS25---26 DMPs), BWS24 additionally near *IGF2\_*3′UTR (3 DMPs).Table 3Number and percentage of significant DMPs in COST DMRsPatient_IDNumber of significant DMPsNumber of significant DMPs in COST DMR% significant DMPs in COST DMPsMLID BWS585715417.97MLID BWS3190322611.88MLID BWS116681388.27MLID BWS227791615.79MLID BWS41742653.73BWS71957412.10BWS221055161.52BWS2591461091.19BWS5133380.60BWS2413,898770.55BWS11110260.54BWS483440.48BWS2347620.42BWS361520.33BWS1108430.28BWS1644110.23BWS990320.22BWS1247410.21BWS1853810.19BWS1754510.18BWS870110.14BWS10151720.13BWS1347900.00BWS1444300.00BWS1555100.00BWS1953800.00BWS2041900.00BWS2146300.00BWS273500.00BWS662100.00

In BWS7, we detected three hypomethylated DMRs (near *NHP2L1*, *IGF1R*, *and L3MBTL)* and one hypermethylated DMR (near *ZDBF2*) with two or more significant DMPs overlapping with COST regions in MLID-BWS patients (Fig. [3](#Fig3){ref-type="fig"}, Additional file [6](#MOESM6){ref-type="media"}: Table S5).Fig. 3Aberrant methylated imprinted DMRs in BWS7 and MLID BWS patients. NC represents confidence interval of beta values in normal controls

In BWS4, we detected alteration of methylation in the primary BWS-associated locus on 11p. In *KCNQ1OT1*, two consecutive hypomethylated DMPs were annotated with delta differences of − 0.37 and − 0.45. These two DMPs exhibited a stable methylation status in control with an adequate beta mean of 0.56 and 0.51 and standard deviation (SD) 0.03 and 0.04, respectively. Hypomethylation in this locus was not detected with standard diagnostics (see Additional file [1](#MOESM1){ref-type="media"}). Additional sequencing of this region (Sanger sequencing) showed the presence of SNP (rs190535862; minor allele frequency (MAF), *A* = 0.005; *G* \> *A*) in one of the two hypomethylated CpGs positions in this patient, explaining the detected hypomethylation.

BWS22 displayed hypermethylation in *H19* TSS DMR in three nonconsecutive probes. The absolute delta difference in only one of these three DMPs was larger than 10%. However, all of them had a significant adj.P-value_M (all delta differences and adj.*P*-values assigned to each DMP per patient are listed in Additional file [1](#MOESM1){ref-type="media"}). The methylation status of all three DMPs in control was stable with SD 0.02, 0.01, and 0.02, respectively. Sanger sequencing did not show the presence of a SNP in this region. Moreover, we detected hypermethylation in this patient in two other imprinted loci assigned to *MEST* and *PEG13* (two significant DMPs in each).

The genomic locations of COST regions and the complete COST region analysis are listed in the Additional file [7](#MOESM7){ref-type="media"}: Table S6, Additional file [8](#MOESM8){ref-type="media"}: Table S7, and Additional file [9](#MOESM9){ref-type="media"}: Table S8.

Searching for DMRs shared between BWS patients in the methylome {#Sec13}
---------------------------------------------------------------

We compared significant DMPs between patients, including MLID-BWS patients.

Regarding hypermethylation comparative analysis, we detected 6613 significant DMPs shared between a minimum of two BWS patients. A majority of them were shared between BWS24 and BWS25 in whom we detected hypermethylation throughout the methylome. We observed an increased number of hypermethylated DMPs annotated to the protocadherin gamma gene cluster located on chromosome 5. Thirty DMPs assigned to this cluster displayed hypermethylation in three MLID-BWS patients and BWS7. Further inspection of the 130 healthy individuals previously collected in our lab for diverse genome-wide methylation studies did not reveal any abnormal methylation in this region suggesting that alteration of methylation of this locus is specific for these patients (Table [4](#Tab4){ref-type="table"}). Moreover, unsupervised hierarchical clustering of this region showed that the DNA pattern of BWS7 and three MLID-BWS patients fell in the same cluster (Fig. [4](#Fig4){ref-type="fig"}b).Table 4Most frequently altered methylated DMPs (the recurrent analysis)Hypomethylated DMPs in DUSP22MLID BWS1BWS1BWS2BWS3BWS11BWS19BWS22Number of patientscg07332563○○○○○○○7cg21548813○○○○○○○7cg03395511○○○○○○○7cg15383120○○○○○○○7cg18110333○○○○○○○7cg05064044○○○○○○○7cg11235426○○○○○○○7cg01516881○○○○○○○7cg26668828○○○○○○○7cg01171360○○○○○○○7Hypermethylated DMPs in protocadherin gamma gene cluster located on chromosome 5MLID BWS1MLID BWS2MLID BWS3MLID BWS4BWS7BWS24BWS25Number of patientscg10933186○○○○4cg20717585○○○○4cg16574737○○○○4cg27079776○○○○4cg20433262○○○○4cg01418385○○○3cg13725516○○○3cg02580763○○○3cg13972793○○○3cg04160343○○○3cg19928377○○○3cg23985374○○2cg07242860○○2cg14472390○○2cg27553119○○2cg21537235○○2cg24120669○○2cg19689427○○2cg16579158○○2cg17760318○○2cg01301252○○2cg24996161○○2cg00978427○○2cg03086707○○2cg00633552○○2cg02022808○○2cg24633027○○2cg25564433○○2cg08292467○○2cg02742676○○2○ statistically significant aberrant methylationFig. 4The heat maps of altered methylated probes from the comparative analysis. The blue beam represents healthy individuals from three different cohorts, and the red beam represents BWS patients. Normal controls come from three different batches that are visible on the plots. **a** Unsupervised hierarchical clustering of the beta values of the significantly hypomethylated probes annotated to the *DUSP22* detected in the current study. **b** Unsupervised hierarchical clustering of the beta values of the significantly hypermethylated probes annotated to the protocadherin gamma gene cluster detected in the current study

We detected 1521 significantly hypomethylated DMPs shared between a minimum of two patients. More than 20% were annotated to imprinted loci (as reported above in the COST regions analysis) and shared between MLID-BWS patients. A majority of these shared probes represented single DMPs.

The most often altered methylated region was annotated to *DUSP22.* Ten DMPs located in this region shared hypomethylation between seven patients: MLID-BWS1, BWS1, BWS2, BWS3, BWS11, BWS19, and BWS22. The visualization of 130 healthy individuals showed variability in this specific region for healthy individuals (Fig. [4](#Fig4){ref-type="fig"}a), strongly suggesting that the hypomethylation of DMPs located near *DUSP22* detected in the current study is not specific for BWS.

The complete comparative analysis is listed in Additional file [10](#MOESM10){ref-type="media"}: Table S9.

Discussion {#Sec14}
==========

We analyzed the methylation status of DNA in the cohort of 25 BWS patients devoid of any known (epi)genetic cause. We also included five MLID-BWS patients with known hypomethylated regions. Besides the known loci, we identified 18 other significantly hypomethylated and two hypermethylated imprinted regions. The percentage of significant DMPs in the COST regions was found to be higher in MLID-BWS than in other patients, indicating that the disruption of methylation is enriched in imprinted genes in MLID rather than genome-wide loss of methylation.

In patients BWS24 and BWS25, we detected hypermethylation throughout the methylome. BWS24 displayed hypermethylation in 3% and BWS25 in almost 2% of all the informative probes. This percentage is very high compared to that of other patients in whom hypermethylated DMPs did not exceed 0.44%. Both these patients also displayed hypermethylation in imprinted loci among others in *H19* TSS and additionally in *IGF2*\_3′UTR in BWS24. However, the changes in methylation in these regions are subtle and do not clearly explain the development of BWS phenotype in these patients. The number of significant DMPs located in the COST regions was lower than that found in MLID-BWS patients, indicating aberrant methylation is not specific for imprinted regions, which suggests a different underlying mechanism to that in MLID patients. It has been shown recently that mutations in chromatin modifying genes cause aberrant methylation patterns throughout the genome. Possibly the methylation profile in our patients is caused by a mutation in such a gene \[[@CR11]\].

In patient BWS7, we detected several hypomethylated imprinted loci that overlapped with MLID-BWS patients (*NHP2L1*, *IGF1R*, *L3MBT*L, and *ZDBF2*). All detected regions were previously described not only in MLID-BWS patients but also in other imprinting disorders showing MLID. For example, Docherty et al. described hypomethylation in the *NHP2LI* locus in Silver-Russell syndrome with MLID \[[@CR12]\], and Rochtus et al. described hypomethylation in the *IGF1R* locus in patients with pseudohypoparathyroidism \[[@CR13]\].

The most interesting of these four loci seems to be a locus situated near *IGF1R*. *IGF1R* is a receptor for *IGF1* and *IGF2*. *IGF2* is overexpressed in BWS cases with a gain of methylation at *H19* TSS DMR. *IGF1R* is normally a biallelic expression. However, Howard et al. reported a BWS case with monoallelic expression of the maternal *IGF1R* in a normal kidney, in Wilms tumor, and in lymphocytes. It is worth mentioning here that BWS patients with the gain of methylation in *H19* TSS DMR have a risk of Wilms tumor development \[[@CR14]\]. In addition, many publications demonstrate that *IGF1R* affects birth weight and postnatal growth. This applies to both the overgrowth and the growth retardation. Okubo et al. reported two children with an abnormal growth were related to *IGF1R*. The first child with a growth retardation and hypoglycemia had only one copy of *IGF1R* while the second with overgrowth showed three copies of *IGF1R*. This suggests that loss of expression of *IGF1R* leads to growth retardation and over expression leads to overgrowth \[[@CR15]\]. In BWS7, MLID-BWS3, MLID-BWS4, and MLID-BWS5, we detected a significant hypomethylation in the locus near *IGF1R*. The major feature of BWS is overgrowth, and we can speculate that hypomethylation of the *IGF1R* locus may lead to the over-expression of this gene and cause overgrowth in our patients. However, additional studies are necessary to ascertain this causal relationship.

In BWS4, we observed hypomethylation in two consecutive DMPs located in imprinted locus *KCNQ1OT1*, primarily associated with BWS. A SNP was present at the hybridization site of the probes of both CpGs. Knowledge of the fact that the existence of a SNP in the examined CpG can have an impact on methylation readouts \[[@CR16]\], we believe that hypomethylation of the other DMP is a result of the cross-reaction between the two probes. This led to the conclusion that this finding is probably not the cause of BWS in this patient, and one should consider the presence of a SNP when only one or two nearby CpGs show hypomethylation.

BWS22 displayed gain of methylation in three nonconsecutive DMPs in the imprinted *H19* locus, and only one DMP had a delta difference larger than 10%. Although significant, it is not clear whether such a small number of aberrant DMPs can be causative for BWS. It may be that, due to tissue mosaicism, other tissues in this patient are more affected and aberrant methylation covers a larger region. Alders et al. reported three BWS patients with epigenetic changes in tongue and buccal swab but with normal methylation status in the blood \[[@CR17]\]. The tissue mosaicism may also be a cause of BWS in other patients in our cohort.

We observed enriched hypermethylation in 30 DMPs annotated to the protocadherin gamma gene cluster located on chromosome 5 in three of five MLID-BWS patients and BWS7. The additional visualization of methylation patterns in healthy individuals showed that hypermethylation in this locus was specific for these three patients. Interestingly, BWS7 showed disturbed methylation in imprinted regions overlapping with MLID-BWS cases as well. This strengthens our hypothesis that BWS7 has MLID and led us to the conclusion that MLID patients display similar methylation patterns not only in imprinted but also in non-imprinted regions.

One region near the *DUSP22* gene showed profound hypomethylation in seven BWS patients, involving ten DMPs. A similar hypomethylation pattern was observed in 27 of 130 healthy individuals, indicating hypomethylation in this locus is not specific for BWS. The differential methylation in this gene has been so far reported in several methylation studies \[[@CR18]--[@CR20]\]. We observed aberrant methylation in this gene in other cohorts (data not published) as well. Steegenga et al. described changes in methylation in *DUSP22* in an age-related study and showed that changes in methylation in this gene do not influence gene expression and aberrant methylation may be due to interindividual variation \[[@CR21]\]. Our results are in agreement with this hypothesis.

In summary, in our cohort of 25 BWS patients without a molecular conformation, we identified one patient with MLID, two patients with genome-wide hypermethylation, and one patient with only very subtle hypermethylation at the H19 locus. The results described here suggest that the HumanMethylation array is highly sensitive and can even detect a small alteration of methylation, which is helpful in confirming the diagnosis.

Conclusions {#Sec15}
===========

BWS diagnosis cannot always be confirmed by routine diagnostic tests.

The results of our study indicate that the BWS phenotype may result from different epi(genetic) aberrations, and these aberrations do not necessarily have to be in the primarily disease-associated locus on 11p15. Additionally, we showed that the HumanMethylation450 array may be used to extend BWS diagnostics. This study points to unknown epi(genetic) mechanisms and paves the way for development of new diagnostics tests for BWS.

Limitations {#Sec16}
-----------

Our study was limited to lymphocytes, and we were not able to determine the methylation status in the imprinted region on chromosome 11p in other tissues and thereby excluded tissue mosaicism.

Moreover, the single case method does not include a correction for blood cell distribution, which may influence the results.

Additional files
================

 {#Sec17}

Additional file 1:Contains additional information about (1) quality control, (2) pre-processing data and statistical methods, (3) estimation of the cell type distribution, (4) standard diagnostics, and (5) additional inspection of primary BWS associated loci at 11p15.5. (DOCX 555 kb) Additional file 2:**Table S1.** Significant hypermethylated DMPs per patient. (XLSX 3887 kb) Additional file 3:**Table S2.** Significant hypomethylated DMPs per patient. (XLSX 1129 kb) Additional file 4:**Table S3.** The estimation of the cell types distribution. (CSV 4 kb) Additional file 5:**Table S4.** The calculation of *P* values of the cell types distribution per patient. (XLSX 47 kb) Additional file 6:**Table S5.** The summary of identified aberrant CpGs within COST regions. (DOCX 25 kb) Additional file 7:**Table S6.** Genomic locations of imprinted loci---COST regions. (CSV 2 kb) Additional file 8:**Table S7.** Significant hypermethylated DMPs within the COST regions (per patient). BWS patients that did not display aberrant methylation in imprinted COST regions are not included in this table. (XLSX 38 kb) Additional file 9:**Table S8.** Significant hypomethylated DMPs overlapped with COST regions. BWS patients that did not display aberrant methylation in imprinted COST regions are not included in this table. (XLSX 98 kb) Additional file 10:**Table S9.** Results of the comparative analysis. (XLSX 5326 kb)

BWS

:   Beckwith-Wiedemann syndrome

DHS

:   DNase I hypersensitivity site

DMP

:   Differentially methylated position

DMR

:   Differentially methylated region

FDR

:   False discovery rate

HRMA

:   High resolution melting analysis

IDs

:   Imprinting disorders

MAF

:   Minor allele frequency

MLID

:   Multi-locus imprinting disturbance

MS-MLPA

:   Methylation-specific multiplex ligation-dependent probe amplification

QC

:   Quality control

SNP

:   Single nucleotide polymorphism

TSS

:   Transcription start site
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